Lightnews — Scholar-powered news

Reposted by Sherene Loi MD

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · May 30

The chemo-free combo of Ribo+Let+trastuzumab led to mOFS 30.4 months, good ORR, and minimal cardiac toxicity in this ph2 1L Korean study. #ASCO25 @oncoalert.bsky.social

1 2 6

Sherene Loi MD @loisher.bsky.social · May 30

Pleased to be part of these elections!

OncoDaily @oncodaily.bsky.social · May 30

Shaping the Future of Oncology: ESMO Elections 2025 Now Open!
@myesmo.bsky.social

oncodaily.com/insight/esmo...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMOElections

ESMO Elections 2025: Shaping the Future of Oncology

The European Society for Medical Oncology (ESMO) is preparing for its pivotal 2025 elections.

oncodaily.com

2

Reposted by Sherene Loi MD

ESMO - European Society for Medical Oncology @myesmo.bsky.social · May 14

In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups.

Full article in the #ESMODailyReporter

🔗 ow.ly/rtbo50VSyiN

2 3

Reposted by Sherene Loi MD

OncoDaily @oncodaily.bsky.social · May 17

DIAmOND Trial at ESMO Breast 2025 Shows Activity of Durvalumab and Tremelimumab in Trastuzumab-Resistant HER2+ Breast Cancer
@myesmo.bsky.social @loisher.bsky.social

oncodaily.com/science/diam...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DIAmOND #ESMOBreast25

DIAmOND Trial at ESMO Breast 2025 Shows Activity of Durvalumab and Tremelimumab in Trastuzumab-Resistant HER2 Positive Breast Cancer - OncoDaily

Dual checkpoint blockade with tremelimumab + durvalumab shows promise in HER2-positive advanced breast cancer with trastuzumab resistance in the DIAmOND trial at ESMO 2025.

oncodaily.com

1 7

Sherene Loi MD @loisher.bsky.social · Apr 22

🎈🎈🎈news day for #HER2 pos #breastcancer. Will look fwd to seeing the HR and comparable toxicity profiles
www.astrazeneca.com/media-centre...

Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive met...

www.astrazeneca.com

Reposted by Sherene Loi MD

The ASCO Post @ascopost.bsky.social · Apr 16

Does the timing of neoadjuvant nivolumab initiation affect outcomes in early-stage triple-negative breast cancer?
A phase II study led by Dr. Sherene Loi explores this critical question.
Read more: ascopost.com/news/march-2...
#TripleNegativeBreastCancer #Immunotherapy

Triple-Negative Breast Cancer: Neoadjuvant Nivolumab Initiation

The phase II Neo-N trial investigated the activity of two differing schedules of neoadjuvant nivolumab initiation—lead-in or concurrent—with 12 weeks of carboplatin and paclitaxel in patients with ear...

ascopost.com

1 3

Reposted by Sherene Loi MD

Stephanie L. Graff, MD FACP FASCO @drsgraff.bsky.social · Mar 12

Dr. Janni reviews ongoing ctDNA trials w/de-escalation, escalation. Starts with historical perspective that attempts to use CT/body imaging for early disease recurrence did NOT improve overall survival, only increased detection of recurrence (lead time bias). #SGBCC2025

1 4

Reposted by Sherene Loi MD

Breast International Group @bigxresearch.bsky.social · Mar 5

#SGBCC2025 - The 19th St.Gallen International #BreastCancer Conference 2025 is almost here!💡 Key BIG 🔬 experts like Drs. Giuseppe Curigliano,
@loisher.bsky.social, @tanjaspanic.bsky.social, & more will be there. Don't miss their insights! @oncoalert.bsky.social #bcsm

2 6

Sherene Loi MD @loisher.bsky.social · Feb 22

@thelancet.bsky.social the Lancet summit for cancer control in China 🇨🇳
Great discussion for #breastcancer #lungcancer #GIcancers

3

Reposted by Sherene Loi MD

Marleen Kok, MD PhD, NKI @marleenkok.bsky.social · Feb 7

Many good things to say on this story @oncoalert.bsky.social @naturemedicine.bsky.social: 1) serious biomarker work from a pharma-sponsored trial👏👏 2) a tumor historically consid cold 🥶can respond to aPD1 🤩3) we need to redefine ER+ disease to enable personalized treatm✍️

Sherene Loi MD @loisher.bsky.social · Feb 4

summary CM-7FL @oncoalert.bsky.social
@naturemedicine.bsky.social link: rdcu.be/d8Cw4.
Here Nivo ⬆️ pCR rates in high grade HR+ BC. Increasing pCR rates in this subtype is HARD! PD-L1+ & #TIL higher pCR. This study will change how we think about HR+BC- some are immunogenic & need PD-1i with chemo

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial

Nature Medicine - In the CheckMate 7FL trial, neoadjuvant nivolumab and chemotherapy in patients with newly diagnosed, high-risk estrogen receptor-positive breast cancer led to an increased...

rdcu.be

2 3

Sherene Loi MD @loisher.bsky.social · Feb 10

🚩pleased to share our latest "Genomic Characterisation and Prognostic Significance of HER2–Low, HR+, Early #Breastcancer From the BIG 1-98 and SOFT Clinical Trials" #bcsm using centrally reviewed HER2 IHC from 2 large clinical trials #IBCSG @oncoalert.bsky.social 👏
ascopubs.org/doi/10.1200/...

Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials | JCO P...

PURPOSETo investigate whether hormone receptor–positive, human epidermal growth factor receptor 2–low (HR+HER2-low) versus HR+HER2-zero early breast cancers have distinct genomic and clinical characte...

ascopubs.org

2 6

Sherene Loi MD @loisher.bsky.social · Feb 8

🎈our recent collaborative review on “Complexities of Cancer” highlighted here 👏👏👏 🙏 @cp-cell.bsky.social as well as many other seminal articles- well worth a look 👀 @oncoalert.bsky.social

Cell - a Cell Press journal @cp-cell.bsky.social · Jan 23

As we wrap up our year-long celebration of Cell’s 50th anniversary, we present “Cell Line: 2014–2024,” a timeline highlighting a set of exceptional scientific works—both landmark papers and essential reviews—published in the journal. www.cell.com/action/showP...

Screen capture of a Timeline article of significant papers published in Cell during the period from 2014 to 2024. The link in the post provides access to a PDF of the full article.

2 4

Sherene Loi MD @loisher.bsky.social · Feb 5

Remembering Jose Baselga and the superstar 👏⭐️ he was

Tatiana Prowell, MD @tmprowell.bsky.social · Feb 5

#MedSky #NeuroSky

These are non-clinical data, but if you know anything about prion diseases, you should stop right now & read this paper. Remembering oncologist Jose Baselga who died in 2021 of sporadic CJD. He’d have given this team a long standing ovation. 💪👏👏

www.science.org/doi/10.1126/...

Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor

Prion disease is caused by misfolding of the prion protein (PrP) into pathogenic self-propagating conformations, leading to rapid-onset dementia and death. However, elimination of endogenous PrP halts...

www.science.org

2

Sherene Loi MD @loisher.bsky.social · Feb 4

summary CM-7FL @oncoalert.bsky.social
@naturemedicine.bsky.social link: rdcu.be/d8Cw4.
Here Nivo ⬆️ pCR rates in high grade HR+ BC. Increasing pCR rates in this subtype is HARD! PD-L1+ & #TIL higher pCR. This study will change how we think about HR+BC- some are immunogenic & need PD-1i with chemo

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial

Nature Medicine - In the CheckMate 7FL trial, neoadjuvant nivolumab and chemotherapy in patients with newly diagnosed, high-risk estrogen receptor-positive breast cancer led to an increased...

rdcu.be

3 10

Sherene Loi MD @loisher.bsky.social · Jan 31

🎈Adjuvant Atezo for fully resected #TNBC #breastcancer is of NO benefit. We’ll see soon results from SWOG trial in re post neoadjuvant (w/o IO). Exposure to antigen and draining LN seems v. important for ICB efficacy. @oncoalert.bsky.social #bcsm

Breast International Group @bigxresearch.bsky.social · Jan 30

🚨 The final analysis of the phase 3 #ALEXANDRA/IMpassion030 study on adding atezolizumab to post-op chemo for high-risk early-stage #TNBC is out in @jama.com, contributing to a greater understanding of immunotherapy in #breastcancer👉 jamanetwork.com/journals/jam...
@mignatiadis.bsky.social

1 5

Sherene Loi MD @loisher.bsky.social · Jan 22

➡️➡️ very exciting news for estrogen receptor + #breastcancer- a subset is very immunogenic - this data changes the way we think about T cell immunosurveillance in this BC subtype
👏👏👏

Peter MacCallum Cancer Centre @petermaccc.bsky.social · Jan 22

A Peter Mac international clinical trial led by @loisher.bsky.social has shown adding #immunotherapy drug nivolumab + chemo before surgery can dramatically improve #breastcancer cure rates.

On the front page of today's Herald Sun or more here: www.petermac.org/about-us/new...

3

Sherene Loi MD @loisher.bsky.social · Jan 20

Next time I’d love to be there!

1 1

Reposted by Sherene Loi MD

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · Jan 19

📌 Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges
👉🏻 sciencedirect.com/science/articl…
@ilanaschlam.bsky.social @loisher.bsky.social
@oncoalert.bsky.social

4 5

Sherene Loi MD @loisher.bsky.social · Jan 16

Looking fwd to the joint annual meeting of 🇯🇵 #jcog #kbcs 🇰🇷#tibcs 🇹🇼 and @BCTrialsANZ 🇦🇺 in #nagoya #breastcancer trials

1

Sherene Loi MD @loisher.bsky.social · Jan 15

Great fun discussing #breastcsncer #immunotherapy in #japan #nagoya 🙏

2

Reposted by Sherene Loi MD

Peter MacCallum Cancer Centre @petermaccc.bsky.social · Dec 3

We are incredibly proud to announce that five Peter Mac researchers have been named in Clarivate's top 1% most cited researchers worldwide for 2024.

Read more: www.petermac.org/about-us/new...

3 9

Sherene Loi MD @loisher.bsky.social · Jan 12

HNY everyone! Our latest review @natrevcancer.bsky.social on the #breastcancer immune microenvironment is pinned here. Looking fwd to a very exciting 2025.
rdcu.be/d51vW

Towards targeting the breast cancer immune microenvironment

Nature Reviews Cancer - In this Review, Harris et al. summarize the dynamic changes of the immune breast tumour microenvironment (TME) that take place during disease progression and in response to...

rdcu.be

1 4 15

Sherene Loi MD @loisher.bsky.social · Dec 12

#sabcs24
HR+HER2+ #breastcancer now finally its own entity 👏👏👏

Erika Hamilton MD, FASCO @erikahamilton9.bsky.social · Dec 12

Wow, PATINA shows 15 month improved PFS in 1st line HER-2 when palbociclib is added to ET +HER-2 antibodies in maintenance 1st line setting after chemo induction.

👏

#bcsm
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

www.businesswire.com/news/home/20...

Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer

Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) today announced results from the Phase 3 PATINA trial demonstrating that the addition

www.businesswire.com

1 6

Sherene Loi MD @loisher.bsky.social · Dec 12

#sabcs24
State of the Art session speakers Immune bio markers #til thanks to @balkolab @psharmab

1 5